Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

被引：0

作者：

Roch Houot

Guillaume Cartron

Fontanet Bijou

Sophie de Guibert

Gilles A. Salles

Christophe Fruchart

Krimo Bouabdallah

Marie Maerevoet

Pierre Feugier

Steven Le Gouill

Hervé Tilly

Rene-Olivier Casasnovas

Cécile Moluçon-Chabrot

Eric Van Den Neste

Pierre Zachee

Marc Andre

Christophe Bonnet

Corinne Haioun

Achiel Van Hoof

Koen Van Eygen

Lysiane Molina

Emmanuelle Nicolas-Virelizier

Philippe Ruminy

Franck Morschhauser

机构：

[1] University Hospital of Rennes,Department of Clinical Hematology

[2] Inserm 0203,Department of Clinical Hematology

[3] University of Rennes,Department of Hematology

[4] University Hospital of Montpellier,undefined

[5] UMR CNRS 5235,undefined

[6] University of Montpellier,undefined

[7] French Blood Institute,undefined

[8] Department of Hematology,undefined

[9] Centre Hospitalier Lyon-Sud,undefined

[10] Institut d’Hématologie de Basse Normandie (IHBN),undefined

[11] CHU,undefined

[12] Haematology,undefined

[13] CHU de Bordeaux,undefined

[14] Hematology,undefined

[15] Institut Jules Bordet,undefined

[16] CHU et INSERM 954,undefined

[17] Nancy Université,undefined

[18] Nantes University Hospital and UMR892 INSERM,undefined

[19] Centre Henri Becquerel,undefined

[20] Inserm U918,undefined

[21] Université de Rouen,undefined

[22] IRIB,undefined

[23] Hematology,undefined

[24] University Hospital,undefined

[25] Hematology Department,undefined

[26] CHU Clermont Ferrand,undefined

[27] Department of Hematology,undefined

[28] Cliniques Universitaires Saint-Luc,undefined

[29] AZ GROENINGE,undefined

[30] Hematology Department,undefined

[31] CHU UCL NAMUR,undefined

[32] Clinical Hematology,undefined

[33] CHU University of Liège,undefined

[34] Hôpital Henri Mondor,undefined

[35] Unité Hémopathies Lymphoide,undefined

[36] General Hospital St-Jan,undefined

[37] ZNA Stuivenberg,undefined

[38] Hematology,undefined

[39] CHU de Grenoble,undefined

[40] Hematology Department,undefined

[41] Centre Léon Bérard,undefined

[42] Université de Lille/ hopital Claude Huriez,undefined

来源：

Leukemia | 2019年 / 33卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：776 / 780

页数：4

共 50 条

[31] Preliminary results from a phase II study of lenalidomide monotherapy in Relapsed/Refractory aggressive non-Hodgkin's lymphoma. [J].

Wiemik, Peter H. ;

Lossos, Izidore ;

Tuscano, Joseph ;

Justice, Glen ;

Vose, Julie M. ;

Pietronigro, Dennis ;

Takeshita, Kenichi ;

Ervin-Haynes, Annette ;

Zeldis, Jerome B. ;

Habermann, Thomas M. .

BLOOD, 2006, 108 (11) :160A-161A

[32] Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma [J].

Christian, Beth A. ;

Huang, Ying ;

Ayyappan, Sabarish ;

Baiocchi, Robert A. ;

Brammer, Jonathan E. ;

Epperla, Narendranath ;

Jaglowski, Samantha ;

William, Basem M. ;

Awan, Farrukh T. ;

Maddocks, Kami J. ;

Blum, Kristie A. .

BLOOD, 2019, 134

[33] Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma [J].

Kuruvilla, John ;

Taylor, Diane ;

Wang, Lisa ;

Blattler, Chantale ;

Keating, Armand ;

Crump, Michael .

BLOOD, 2008, 112 (11) :1049-1049

[34] Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study [J].

Diefenbach, Catherine ;

Kahl, Brad S. ;

McMillan, Andrew ;

Briones, Javier ;

Banerjee, Lalita ;

Cordoba, Raul ;

Miall, Fiona ;

Burke, John M. ;

Hirata, Jamie ;

Jiang, Yanwen ;

Paulson, Joseph N. ;

Chang, Yi Meng ;

Musick, Lisa ;

Abrisqueta, Pau .

LANCET HAEMATOLOGY, 2021, 8 (12) :E891-E901

[35] A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501). [J].

Morrison, V. A. ;

Jung, S. ;

Johnson, J. L. ;

Leonard, J. ;

Cheson, B. D. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[36] AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma [J].

Leonard, John P. ;

Trneny, Marek ;

Izutsu, Koji ;

Fowler, Nathan H. ;

Hong, Xiaonan ;

Zhu, Jun ;

Zhang, Huilai ;

Offner, Fritz ;

Scheliga, Adriana ;

Nowakowski, Grzegorz S. ;

Pinto, Antonio ;

Re, Francesca ;

Fogliatto, Laura Maria ;

Scheinberg, Phillip ;

Flinn, Ian W. ;

Moreira, Claudia ;

Cabecadas, Jose ;

Liu, David ;

Kalambakas, Stacey ;

Fustier, Pierre ;

Wu, Chengqing ;

Gribben, John G. ;

Calaminici, Maria ;

Copie-Bergman, Christiane ;

Lopez-Guillermo, Armando ;

O'Connor, Owen ;

Williams, Michael ;

Suciu, Stefan ;

Levine, Benjamin ;

Kern, Julie .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) :1188-+

[37] Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study [J].

Flowers, Christopher ;

Zinzani, Pier Luigi ;

Mayer, Jiri ;

Bijou, Fontanet ;

de Oliveira, Ana C. ;

Song, Yuqin ;

Zhang, Qingyuan ;

Merli, Michele ;

Bouabdallah, Krimo ;

Ganly, Peter S. ;

Zhang, Huilai ;

Yuen, Sam ;

Kingsley, Ed ;

Assouline, Sarit E. ;

Auer, Rebecca ;

Kim, Pil ;

Greenbaum, Adam ;

Huang, Sha ;

Delarue, Richard ;

Trotman, Judith .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[38] A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma [J].

Fowler, Nathan ;

Pinto, Raisa M. ;

Cheah, Chan Yoon ;

Neelapu, Sattva S. ;

Turturro, Francesco ;

Hagemeister, Fredrick B. ;

Romaguera, Jorge E. ;

Fanale, Michelle A. ;

Fayad, Luis E. ;

Forbes, Sheryl ;

Khan, Janine ;

Feng, Lei ;

Samaniego, Felipe ;

Nastoupil, Loretta .

BLOOD, 2015, 126 (23)

[39] A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma [J].

Kim, Myung Sun ;

Banerjee, Titas ;

Chen, Andy ;

Danilov, Alexey ;

MacKinnon, Renee ;

Thurlow, Bria ;

Thakurta, Sujata ;

Orand, Kirsten ;

Degnin, Catherine ;

Park, Byung ;

Spurgeon, Stephen E. .

LEUKEMIA & LYMPHOMA, 2023, 64 (03) :722-724

[40] Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL) [J].

Nastoupil, Loretta J. ;

Westin, Jason R. ;

Hagemeister, Fredrick B. ;

Lee, Hun Ju ;

Fayad, Luis ;

Samaniego, Felipe ;

Ahmed, Sairah ;

Claret, Linda ;

Steiner, Raphael E. ;

Nair, Ranjit ;

Parmar, Simrit ;

Rodriguez, Maria Alma ;

Wang, Michael L. ;

Green, Michael R. ;

Davis, Eric ;

Neelapu, Sattva S. ;

Fowler, Nathan H. .

BLOOD, 2019, 134

← 1 2 3 4 5 →